Equities researchers at StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO – Get Free Report) in a report released on Saturday. The firm set a “sell” rating on the medical device company’s stock.
NeuroMetrix Stock Performance
Shares of NURO stock opened at $4.58 on Friday. The company has a market cap of $9.21 million, a P/E ratio of -0.73 and a beta of 2.29. NeuroMetrix has a fifty-two week low of $2.66 and a fifty-two week high of $5.56. The stock has a 50 day simple moving average of $3.88 and a two-hundred day simple moving average of $3.86.
NeuroMetrix (NASDAQ:NURO – Get Free Report) last released its earnings results on Tuesday, August 6th. The medical device company reported ($0.74) earnings per share (EPS) for the quarter. The company had revenue of $0.77 million for the quarter. NeuroMetrix had a negative net margin of 181.04% and a negative return on equity of 41.74%.
NeuroMetrix Company Profile
NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.
See Also
- Five stocks we like better than NeuroMetrix
- How to Effectively Use the MarketBeat Ratings Screener
- Is Spotify Stock Poised to Soar? Options Traders Think So
- What does consumer price index measure?
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.